Dimethylformamide → Rifampicin

HRID 46715

反応式

HRID 46715 の反応式
[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:34](=[O:35])[C:4](=[C:5]([C:32](=[O:33])[CH:31]=4)[C:6]=2[C:10]3=[O:11])[C:3]=1[OH:50])=[O:28].[CH3:51]N(C)C=O.C(N1CN(C(C)(C)C)CN(C(C)(C)C)C1)(C)(C)C.[NH2:74][N:75]1[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]1>C(O)(=O)C>[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:31](/[CH:51]=[N:74]/[N:75]5[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]5)=[C:32]([OH:33])[C:5]([C:6]=2[C:10]3=[O:11])=[C:4]([C:34]=4[OH:35])[C:3]=1[OH:50])=[O:28]

参加物

6

反応物 4

HCID 6228DimethylformamideHCID 663521,3,5-Tris(1,1-dimethylethyl)hexahydro-1,3,5-triazineHCID 813491-Amino-4-methylpiperazineHCID 6436726Rifamycin S

生成物 1

HCID 135398735Rifampicin

試薬・触媒・溶媒 1

HCID 176Acetic Acid溶媒

実験手順

15 g. Rifamycin S are dissolved in 50 ml. dimethylformamide and 5.5 g. 1,3,5-tri-(tert.-butyl)-hexahydro-1,3,5-triazine are added to the solution. The reaction mixture is then kept at 75° C. for about 3 hours and 1-amino-4-methylpiperazine, acidified with acetic acid, added directly according to the procedure described in Example 1, followed by analogous working up to give substantially pure rifampicin.

後処理

  1. additionadded directly

出典と根拠

ORDレコード
ord-1bae79cdb4cd473f92543be6b20fce4c
出典データセット
uspto-grants-1979_11
特許番号
US04174320

関連ノート

読み込み中…